DES in Thrombosed Coronary Lesions

Jim Gustafson
Sr. Vice President
R&D, Engineering, Clinical Evaluation
Possis Medical, Inc.
Presenting Thrombus Increases PCI Risk

“Why is it important to identify thrombus prior to PCI? Intracoronary thrombus is associated with increased risk of embolization, no-reflow, procedural MI, acute closure, stent thrombosis, etc.”
– Dr. J Carrozza, Jr., TCT 2003

“Thrombus increases procedural risk.”
– Dr. I Moussa, TCT 2004

“Thrombus increases complications.”
– Dr. R Kuntz, TCT 2004

“Thrombotic cases are always an interventional challenge.”
– Dr. G Dangas, Jan 2005, TCTMD
“Safety and effectiveness have not been established in:
1. Patients with unresolved thrombus at the lesion site.”
6. Patients with a recent AMI where there is evidence of thrombus or poor flow.”
AngioJet® Rheolytic™ Thrombectomy System
AngioJet Action
What evidence, including real-world clinical experience, characterizes DES outcomes in these patient subsets?
Pre-Clinical Evidence

“Thrombus Modulates Arterial Drug Distribution for Drug-Eluting Stents.”

Models:
- Computational
- In vitro
- In-vivo

Measurements:
- Drug capacity
- Drug diffusivity
- Convective velocity
Hwang et. al. conclusions: “Thrombus apposed on stents creates large variations in drug uptake and can act to either increase or decrease wall deposition according to the clot and stent geometry. Arterial deposition of drug from stents deployed in clots will be highly variable and unpredictable unless the clot can be adequately controlled or removed.”
Real-World Clinical Experience

“Current Experience and Role of Rheolytic™ Thrombectomy in the Management of Acute Myocardial Infarction with Large Thrombus Burden”.

*Journal of Invasive Cardiology.*
Eds: Drs. Bruce Brodie and Donald Baim
Six Independent Clinical Experiences:

- 4 retrospective, 2 prospective.
- 5 single site, 1 multi-site.
- 4 single-arm with concurrent reference sample.
- 1 case-controlled.
- 1 randomized.
# 2006 JIC Supplement Patients

<table>
<thead>
<tr>
<th></th>
<th>AngioJet</th>
<th>Ref Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>625</td>
<td>2,438</td>
</tr>
<tr>
<td>STEMI</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>DES</td>
<td>64%*</td>
<td>71%*</td>
</tr>
<tr>
<td>Thrombus</td>
<td>95%*</td>
<td>69%*</td>
</tr>
</tbody>
</table>

*Approximate
**2006 JIC Supplement Outcomes**

**Rheolytic Thrombectomy During PCI for AMI: In-Hospital Mortality**

- **Rheolytic Thrombectomy, N=625**
- **No Rheolytic Thrombectomy (Comparison Group), N=2,438**

<table>
<thead>
<tr>
<th>Study</th>
<th>N (Rheolytic)</th>
<th>N (Comparison)</th>
<th>In-Hospital Mortality (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D. Antoniucci†</td>
<td>3</td>
<td>191</td>
<td>2.7</td>
</tr>
<tr>
<td>R. Matthews</td>
<td>32</td>
<td>11</td>
<td>9.3</td>
</tr>
<tr>
<td>S. Sharma †</td>
<td>52</td>
<td>43</td>
<td>1.9</td>
</tr>
<tr>
<td>G. Sianos †</td>
<td>75</td>
<td>191</td>
<td>2.8</td>
</tr>
<tr>
<td>C. Simonton †</td>
<td>177</td>
<td>101</td>
<td>2.9</td>
</tr>
<tr>
<td>S. Dixon †</td>
<td>239</td>
<td>1021</td>
<td>4.4</td>
</tr>
<tr>
<td>Total of six</td>
<td>625</td>
<td>2438</td>
<td>4.6</td>
</tr>
</tbody>
</table>

- *P=0.0245

*Nine month mortality for Simonton results.
† includes cardiogenic shock
NS does not include cardiogenic shock
Rheolytic Thrombectomy During PCI for AMI: In-Hospital Mortality*

*Nine month mortality for Simonton results.

S includes cardiogenic shock
NS does not include cardiogenic shock

P=0.0245

Total of six registries

N=625 N=2438
Rheolytic Thrombectomy During PCI for AML: In-Hospital Mortality*

<table>
<thead>
<tr>
<th>Study</th>
<th>N=625</th>
<th>N=2,438</th>
</tr>
</thead>
<tbody>
<tr>
<td>D. Antoniucci</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>R. Matthews</td>
<td>32</td>
<td>0</td>
</tr>
<tr>
<td>S. Sharma</td>
<td>1.9</td>
<td>0</td>
</tr>
<tr>
<td>G. Sianos</td>
<td>2.7</td>
<td>4.4</td>
</tr>
<tr>
<td>C. Simonton</td>
<td>2.8</td>
<td>5.4</td>
</tr>
<tr>
<td>S. Dixon</td>
<td>2.9</td>
<td>2.6</td>
</tr>
<tr>
<td>Total of six registries</td>
<td>4.6</td>
<td>4.6</td>
</tr>
</tbody>
</table>

* Nine month mortality for Simonton results.

S includes cardiogenic shock. NS does not include cardiogenic shock.

P=0.0245
Published/presented by Dr. Sianos:

- JIC Supplement July 2006
- EuroPCR May 2006, Paris
- ESC/WCC Sep 2006, Barcelona
- TCT Oct 2006, Washington DC
- AHA Nov 2006, Chicago
Patients

• 900 sequential pts Apr 02 - Dec 04:
  – STEMI < 12 h.
  – 90.1% received DES
  – DES pts received standard anti-platelet Tx
    • SES: clopidogrel 75 mg/d for 3 m; 325 mg/d ASA indefinitely
    • PES: clopidogrel 75 mg/d for 6 m; 325 mg/d ASA indefinitely
  – Average follow-up of 18 m ± 8 m.

• 266 (30%) had baseline TIMI thrombus grade 4.
  – 75 AngioJet (only thrombectomy Tx used).
  – 191 direct stenting.
Stent Thrombosis by Thrombus Size

- Thrombus Grade = 4
  - N = 266
  - Cumulative Stent Thrombosis %
    - 0.7%
    - 4.4%
    - 5.8%

- Thrombus Grade < 4
  - N = 567
  - Cumulative Stent Thrombosis %
    - 0.7%

Follow-Up Months

P < 0.001
**Stent Thrombosis by Thrombus Size**

Cumulative Stent Thrombosis %

- **Thrombus Grade = 4**
  - N = 266
  - P < 0.001
  - 8.2%

- **Thrombus Grade < 4**
  - N = 567
  - 1.3%

Follow-Up Months
Large Thrombus Patients: Stent Thrombosis

Cumulative Stent Thrombosis %

Follow-Up Months

- RT + DES; N = 75
  - Cumulative Stent Thrombosis: 0.0%

- DES Alone; N = 191
  - Cumulative Stent Thrombosis: 11.3%

P = 0.011
Large Thrombus Patients: Survival

RT + DES; N = 75
Survival 92.0 %

DES Alone; N = 191
Survival 82.7 %

P = 0.052

Follow-Up Months
Cumulative Survival %
Large Thrombus Patients: Freedom from MACE

- DES Alone; N = 191
  - Freedom from MACE: 87.7%
- RT + DES; N = 75
  - Freedom from MACE: 69.9%

Follow-Up Months:
- Cumulative MACE-Free Survival %
- P = 0.003

Follow-Up Months: 0 6 12 18 24 30 36
- Cumulative MACE-Free Survival %: 1.0 0.9 0.8 0.7 0.6 0.5 0.4
CONCLUSIONS:

• In STEMI patients receiving DES, large unresolved thrombus at baseline is a major risk factor for stent thrombosis and a driver for MACE.

• AngioJet thrombectomy before DES in STEMI patients with large presenting thrombus significantly reduces stent thrombosis and MACE.
Overall Summary

• Presenting thrombus complicates PCI.
• Unresolved thrombus negatively affects drug delivery in DES use.
• In STEMI, large thrombus is a risk for higher MACE and stent thrombosis.
• In STEMI patients with large thrombus, AngioJet thrombectomy reduces stent thrombosis from 11.3% to 0.0% (p=0.011) out to 2 yrs, and reduces MACE.